Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients
Sarah Zhou(McGill University), Ivan V. Litvinov(McGill University Health Centre), Joël Claveau(Université Laval), Stephanie Ghazal(McGill University), Wilson H. Miller(Jewish General Hospital), Thomas G. Salopek(University of Alberta), Carolyn Nessim(University of Ottawa), Daniel Sikorski(McGill University), François Lagacé(McGill University), Margaret Redpath(McGill University), Teresa M. Petrella(Sunnybrook Health Science Centre), May Chergui(McGill University Health Centre), Honghao Xu(Université Laval), Robert Gniadecki(University of Alberta), Andrei Zubarev(McGill University), Marcus O. Butler(University of Toronto)
Cited by 12
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
|Current Oncology|2020|941
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869